//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
A narrative review summarises recent advances and key trials of radionuclide therapies, including ²²³Ra, ¹⁷⁷Lu‑labelled agents, and emerging α‑emitters, in metastatic castration‑resistant #ProstateCancer. Ther Adv Med Oncol buff.ly/XQWUg2J #RadionuclideTherapy
The treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a huge challenge. Newer radionuclides, such as 223Ra, 177Lu, 225Ac, etc., have ...
journals.sagepub.com
Current status of radionuclide therapies in metastatic castration-resistant prostate cancer - Xin Fei, Rui-Da Huang, Xuan Zhou, Shi-Jie Ye, Nan Nan, Ke-Jie Wang, Qi Ma, 2025
29d
Therapeutic Advances in Medical Oncology